-
AstraZeneca & Daiichi Sankyo’s Enhertu gets EU approval to treat patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy
05 Apr 2025 04:50 GMT
… also are underway.
AstraZeneca and Daiichi Sankyo entered into a global collaboration … Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is … .
With Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes …
-
AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer
04 Apr 2025 11:39 GMT
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has …
-
Daiichi Sankyo announces DESTINY─Gastric05 phase 3 trial of Enhertu initiates in patients with previously untreated HER2 positive advanced gastric cancer
02 Apr 2025 07:53 GMT
… jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Gastric cancer … where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is … is being developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform consists of …
-
EU approves AstraZeneca's Imfinzi─in combo with chemotherapy to treat patients with resectable non─small cell lung cancer
05 Apr 2025 07:44 GMT
… (datopotamab deruxtecan) in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in collaboration with …
-
Enhertu Approved in the EU for Metastatic Breast Cancer
04 Apr 2025 22:59 GMT
… Business, and President and CEO, Daiichi Sankyo, said: “Enhertu continues to evolve … drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and … commercialized by AstraZeneca and Daiichi Sankyo.
Enhertu was approved in the …
-
EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer
04 Apr 2025 23:01 GMT
… press release from the developer, Daiichi Sankyo.1
Previously, the European Medicines … one endocrine therapy. News release. Daiichi Sankyo. April 4, 2025. Accessed April …
-
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
04 Apr 2025 18:16 GMT
… approved AstraZeneca Plc AZN and Daiichi Sankyo's DSKNY Enhertu (trastuzumab … EU, AstraZeneca is due to Daiichi Sankyo $125 million as a milestone …
-
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
04 Apr 2025 15:50 GMT
… Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab … -naïve breast cancer indication.
Daiichi Sankyo discovered this HER2-directed antibody … with no safety concerns observed.
Daiichi Sankyo CEO, president and oncology business …
-
London pre-open: Stocks to edge lower after Thursday's selloff; payrolls in focus
04 Apr 2025 12:43 GMT
… energy transition targets.
AstraZeneca and Daiichi Sankyo's Enhertu has been …
-
AstraZeneca's Enhertu gets fresh EU approval, Science Group ups Ricardo stake further
04 Apr 2025 12:43 GMT
Stocks to watch
AstraZeneca and Daiichi Sankyo's Enhertu has been …
About
© 1995-2025